Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Walter Reed Army Medical Center |
---|---|
Information provided by: | Walter Reed Army Medical Center |
ClinicalTrials.gov Identifier: | NCT00413751 |
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) on pupil diameter under different luminance conditions.
Condition | Intervention |
---|---|
Healthy |
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) |
Study Type: | Observational |
Study Design: | Longitudinal, Convenience Sample, Prospective Study |
Ages Eligible for Study: | 18 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, District of Columbia | |
Walter Reed Army Medical Center | |
Washington, District of Columbia, United States, 20307 |
Principal Investigator: | KRAIG S. BOWER, MD | Walter Reed Army Medical Center |
Study ID Numbers: | WRAMC WU #03-23004 |
Study First Received: | December 19, 2006 |
Last Updated: | December 19, 2006 |
ClinicalTrials.gov Identifier: | NCT00413751 |
Health Authority: | United States: Federal Government |
Large pupils rendering night vision difficulties such as haloes, glare, and monocular diplopia |
Mydriasis Healthy Brimonidine |
Neurotransmitter Agents Adrenergic alpha-Agonists Molecular Mechanisms of Pharmacological Action Adrenergic Agents Therapeutic Uses |
Physiological Effects of Drugs Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions Adrenergic Agonists |